Shigeru Kinoshita

Shigeru Kinoshita

Auto-generated profile, based on publicly available information

Shigeru Kinoshita

Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2018 in New England Journal of Medicine
Verified
Journal Article
Closed access
SKShigeru Kinoshita
Shigeru Kinoshita
NKNoriko Koizumi
Noriko Koizumi
MUMorio Ueno
Morio Ueno
NONaoki Okumura
Naoki Okumura
KIKojiro Imai
Kojiro Imai
JHJunji Hamuro
Junji Hamuro
Corneal endothelial cell (CEC) disorders, such as Fuchs’s endothelial corneal dystrophy, induce abnormal corneal hydration and result in corneal haziness and vision loss known as bullous keratopathy. We investigated whether injection of cultured human CECs supplemented with a rho-associated protein kinase (ROCK) inhibitor into the anterior chamber could increase CEC density.

Verified
Journal Article
Open access
PDF file
Kazuo TsubotaKazuo Tsubota
Kazuo Tsubota
SPStephen Pflugfelder
Stephen Pflugfelder
ZLZuguo Liu
Zuguo Liu
CBChristophe Baudouin
Christophe Baudouin
HKHyo Myung Kim
Hyo Myung Kim
RDReza Dana
Reza Dana
Over the past decades, the number of patients with dry eye disease (DED) has increased dramatically. The incidence of DED is higher in Asia than in Europe and North America, suggesting the involvement of cultural or racial factors in DED etiology. Although many definitions of DED have been used, discrepancies exist between the various definitions of dry eye disease (DED) used across the globe. This article presents a clinical consensus on the definition of DED, as formulated in four meetings with global DED experts. The proposed new definition is as follows: “Dry eye is a multifactorial disease characterized by a persistently unstable and/or deficient tear film (TF) causing discomfort and/or visual impairment, accompanied by variable degrees of ocular surface epitheliopathy, inflammation and neurosensory abnormalities.” The key criteria for the diagnosis of DED are unstable TF, inflammation, ocular discomfort and visual impairment. This definition also recommends the assessment of ocular surface epitheliopathy and neurosensory abnormalities in each patient with suspected DED. It is easily applicable in clinical practice and should help practitioners diagnose DED consistently. This consensus definition of DED should also help to guide research and clinical trials that, to date, have been hampered by the lack of an established surrogate endpoint.

1 April 2021 in Ophthalmology
Verified
Journal Article
Open access
KNKohsaku Numa
Kohsaku Numa
KIKojiro Imai
Kojiro Imai
MUMorio Ueno
Morio Ueno
KKKoji Kitazawa
Koji Kitazawa
HTHiroshi Tanaka
Hiroshi Tanaka
SKShigeru Kinoshita
Shigeru Kinoshita
To report the safety and efficacy of a novel cell injection therapy using cultured human corneal endothelial cells (hCECs) for endothelial failure conditions via the report of the long-term 5-year postoperative clinical data from a first-in-humans clinical trial group. Prospective observational study. This study involved 11 eyes of 11 patients with pseudophakic endothelial failure conditions who underwent hCEC injection therapy between December 2013 and December 2014. All patients underwent follow-up examinations at 1 week, 4 weeks, 12 weeks, and 24 weeks and 1 year, 2 years, 3 years, 4 years, and 5 years after surgery. Specific corneal endothelial cell parameters (i.e., corneal endothelial cell density [ECD], coefficient of variation of area, and percentage of hexagonal cells) and central corneal thickness, best-corrected visual acuity (BCVA) on a Landolt C eye chart, and intraocular pressure (IOP) were recorded. The primary outcome was the change in central ECD after cell injection therapy, and the secondary outcome was corneal thickness, BCVA, and IOP during the 5-year-postoperative follow-up period. At 5 years after surgery, normal corneal endothelial function was restored in 10 of the 11 eyes, the mean ± standard deviation central corneal ECD was 1257 ± 467 cells/mm2 (range, 601-2067 cells/mm2), BCVA improved significantly in 10 treated eyes, the mean visual acuity changed from 0.876 logarithm of the minimum angle of resolution before surgery to 0.046 logarithm of the minimum angle of resolution after surgery, and no major adverse reactions directly related to the hCEC injection therapy were observed. The findings in this study confirmed the safety and efficacy of cultured hCEC injection therapy for up to 5 years after surgery.

1 December 2012 in Ophthalmology
Verified
Journal Article
Closed access
SKShigeru Kinoshita
Shigeru Kinoshita
SASaki Awamura
Saki Awamura
KOKazuhide Oshiden
Kazuhide Oshiden
NNNorihiro Nakamichi
Norihiro Nakamichi
HSHiroyuki Suzuki
Hiroyuki Suzuki
NYNorihiko Yokoi
Norihiko Yokoi

1 June 2013 in Ophthalmology
Verified
Journal Article
Closed access
SKShigeru Kinoshita
Shigeru Kinoshita
KOKazuhide Oshiden
Kazuhide Oshiden
SASaki Awamura
Saki Awamura
HSHiroyuki Suzuki
Hiroyuki Suzuki
NNNorihiro Nakamichi
Norihiro Nakamichi
NYNorihiko Yokoi
Norihiko Yokoi

14 February 2021 in Japanese Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
TGthe ATOM-J. Study Group
the ATOM-J. Study Group
OHOsamu Hieda
Osamu Hieda
THTakahiro Hiraoka
Takahiro Hiraoka
TFTakashi Fujikado
Takashi Fujikado
SISatoshi Ishiko
Satoshi Ishiko
SKShigeru Kinoshita
Shigeru Kinoshita